FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms

NCT06858618 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Safety
Antitumor Activity
PK Profile

Interventions

COMBINATION_PRODUCT: FCN-338 + Azacitidine
COMBINATION_PRODUCT: FCN-338 + erythromycin+ Ara-C

Sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Collaborators

[object Object]